- Ceapro Inc. (CZO) has signed an agreement with the University of Alberta to further scale up the company’s Pressurized Gas eXpanded (PGX) technology
- PGX can enable the creation of fast or slow-release versions of bioactive and can also enable them to be delivered in unique formats like functional beverages or fast-dissolving strips
- The PGX technology scale-up will be focused primarily on processing sodium alginate extracted from brown seaweed and yeast beta glucan extract from brewers’ yeast to form PGX-processed alginate
- Ceapro Inc. (CZO) is down 1.27 per cent, trading at $0.78 per share as of 11:20 a.m. ET
Ceapro (CZO) has signed an agreement with the University of Alberta to further scale up the company’s Pressurized Gas eXpanded (PGX) technology.
The company had demonstrated bioavailability results, PGX Alginate and PGX Yeast Beta-Glucan, as delivery systems for Coenzyme Q10. Ceapro demonstrated significantly improved delivery into the tissues versus the current standard in oral CoQ10 supplementation. This, combined with the data demonstrating that PGX can enable the creation of fast or slow-release versions of CoQ10 and other bioactives and can also enable them to be delivered in unique formats like functional beverages or fast-dissolving strips, support the potential of PGX to transform drug and bioactive delivery, and ultimately enable the creation of potential nutraceutical and pharmaceutical products.
The PGX technology scale-up at AFDP will be focused primarily on processing sodium alginate (ALG) extracted from brown seaweed and yeast beta glucan (YBG) extract from brewers’ yeast to form PGX-processed alginate (PGX-ALG) and PGX-processed yeast beta-glucan (PGX-YBG), both of which have broad applications in both nutraceuticals and pharmaceuticals.
Ceapro’s President and CEO, Gilles Gagnon, said that these never-before-seen results support the decision to scale the PGX Technology to the next level to increase capacity 5 to 10 times as compared to their current demo plant facility.
“The signing of the license agreement to use designated areas within Agri-Food Discovery Place (AFDP) to scale up the PGX technology is an additional deliberate step in this process, which we believe will ultimately lead to the expansion of our pipeline, with significant potential across healthcare markets. This next phase of scale up will allow us to work with commercial partners in nutraceuticals and pharmaceuticals to formulate, test, and commercialize novel products and formulations, including novel functional foods and beverages, novel drugs and various forms of delivery systems.”
He added that the decision to sign the agreement to use AFDP in Edmonton and to invest in a larger customized PGX unit was based on the fact that AFDP’s facility, which is part of the Agricultural Food & Nutritional Science Department at the University of Alberta, has the right infrastructure required to scale-up the PGX Technology to produce human grade material designed for oral delivery required to satisfy regulatory agencies and partners.
This scale up work will be coordinated with two specialized engineering firms that are currently evaluating the design as well as further defining timelines and costs for this project which will be financed using our current cash on hand.
Ceapro Inc. is a Canadian biotechnology company developing extraction technology using materials from oats and other renewable resources. Its technology can support cosmeceutical, nutraceutical, and therapeutic products for humans and animals.
Ceapro Inc. (CZO) is down 1.27 per cent, trading at $0.78 per share as of 11:20 a.m. ET.
